Citação norma APA

Wilbraham, D., Biglan, K. M., Svensson, K. A., Tsai, M., & Kielbasa, W. (2020). Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects. Clin Pharmacol Drug Dev.

Citação norma Chicago

Wilbraham, Darren, Kevin M. Biglan, Kjell A. Svensson, Max Tsai, and William Kielbasa. "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects." Clin Pharmacol Drug Dev 2020.

Citação norma MLA

Wilbraham, Darren, et al. "Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects." Clin Pharmacol Drug Dev 2020.

Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.